ERBB2 and breast carcinoma: Here, the OOC system has been utilized to dissect the role of Trastuzumab, a reference anti-cancer for HER2+ breast cancer patients, on such a tumor-on-chip complemented with CAFs plus hydrogels to reproduce a central endothelium compartment.